QUOTE AND NEWS
StreetInsider.com  Jul 21  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Synta+Pharma+%28SNTA%29+Advances+Ganetespib+into+Phase+3+Extension/9676394.html for the full story.
TheStreet.com  Jun 24  Comment 
DELAFIELD, Wis. (Stockpickr) -- Fireworks are going off in the biotech sector today, after Vertex Pharmaceuticals reported very positive results from an important late-stage drug trial regarding its cystic fibrosis treatment Kalydeco. >> 5...
Benzinga  Jun 18  Comment 
It seems as if mergers and acquisitions in the healthcare sector has become commonplace, with a lot of biotech companies being main targets. Not a week goes by without multiple discussions about the battle between Valeant Pharmaceuticals...
Benzinga  Mar 20  Comment 
IsoRay (NYSE: ISR) shares gained 26.67% to $3.23 as the company announced first pediatric Cesium-131 seeded mesh treatment for metastatic Wilms tumor. BG Medicine (NASDAQ: BGMD) climbed 24.25% to $2.10 after the company reported...
StreetInsider.com  Mar 20  Comment 
IsoRay, Inc. (NYSE: ISR) 25% HIGHER; sees continued upside Synta Pharmaceuticals Corp. (NASDAQ: SNTA) 17.9% HIGHER; today announced the presentation of interim results from the ENCHANT-1 trial, a single-arm multi-center Phase 2 proof-of-concept...
Benzinga  Mar 20  Comment 
Synta Pharmaceuticals (NASDAQ: SNTA) surged 30.53% to $6.20 in the pre-market session on positive interim results from the ENCHANT-1 trial of ganetespib in metastatic breast cancer. Sinovac Biotech (NASDAQ: SVA) shares gained 8.85% to $7.50 in...
StreetInsider.com  Mar 20  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Synta+Pharma+%28SNTA%29+Gains+Following+Positive+Interim+Results+from+the+ENCHANT-1+Trial/9300561.html for the full story.
Benzinga  Mar 12  Comment 
Synta Pharmaceuticals (NASDAQ: SNTA) shares dropped 21.40% to $4.15 in pre-market trading after gaining 4.35% on Tuesday. Stifel Nicolaus downgraded the stock from Hold to Sell. Zogenix (NASDAQ: ZGNX) shares fell 17.40% to $3.75 in the...
Benzinga  Mar 12  Comment 
In a report published Wednesday, Stifel analyst Brian Klein downgraded the rating on Synta Pharmaceuticals (NASDAQ: SNTA) from Hold to Sell. In the report, Stifel noted, “SNTA reported 4Q13 LPS of $(0.31), in line with our $(0.32) estimate....
SeekingAlpha  Mar 11  Comment 
Synta Pharmaceuticals Corp. (SNTA) Q4 2013 Earnings Conference Call March 11, 2014 10:00 ET Executives Steve Bernitz - Senior Vice President, Corporate Development Keith Gollust - Chairman, Board of Directors and Executive Committee ...





You may also be interested in articles related to Synta Pharmaceuticals (SNTA):
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki